Literature DB >> 11500063

Low penetrant hemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region.

S Sachot1, R Moirand, A M Jouanolle, J Mosser, P Fergelot, Y Deugnier, P Brissot, J Y le Gall, V David.   

Abstract

The gene responsible for hemochromatosis (HFE) has been identified on the short arm of chromosome 6, 4.5 Mb telomeric to HLA-A. A major mutation C282Y is closely correlated with the disease, as it accounts for 68 to 100\% of the cases of hemochromatosis. Nevertheless, some C282Y homozygotes subjects have no clinical or biological expression of the disease. Moreover, in Northern European populations a large discrepancy is observed between the number of C282Y homozygotes and the number of diagnosed hemochromatosis patients, suggesting incomplete penetrance of the mutation. To localize and identify the modifying genes, we investigated eight families including C282Y homozygous relatives showing no clinical signs of the disease, in addition to the hemochromatosis patients. Genomic DNA from 20 C282Y homozygotes (10 patients and 10 siblings presenting no or minor biological abnormalities) were studied. Five polymorphisms from the HFE gene were determined by PCR restriction. Extended haplotypes of the 6p21.3 region were constructed with 10 microsatellite markers. All the C282Y homozygotes shared the same HFE polymorphism. The haplotypes presented no significant difference between the probands and their unaffected relatives. These studies suggest that neither HFE polymorphism nor genes surrounding HFE are able to modulate HFE expression. Copyright 2001 Academic Press.

Entities:  

Mesh:

Year:  2001        PMID: 11500063     DOI: 10.1006/bcmd.2001.0394

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  7 in total

1.  Lessons from liver transplantation: flip, flop, and why?

Authors:  P C Adams
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 2.  Forging a field: the golden age of iron biology.

Authors:  Nancy C Andrews
Journal:  Blood       Date:  2008-07-15       Impact factor: 22.113

3.  Penetrance of biallelic SMARCAL1 mutations is associated with environmental and genetic disturbances of gene expression.

Authors:  Alireza Baradaran-Heravi; Kyoung Sang Cho; Bas Tolhuis; Mrinmoy Sanyal; Olena Morozova; Marie Morimoto; Leah I Elizondo; Darren Bridgewater; Joanna Lubieniecka; Kimberly Beirnes; Clara Myung; Danny Leung; Hok Khim Fam; Kunho Choi; Yan Huang; Kira Y Dionis; Jonathan Zonana; Kory Keller; Peter Stenzel; Christy Mayfield; Thomas Lücke; Arend Bokenkamp; Marco A Marra; Maarten van Lohuizen; David B Lewis; Chad Shaw; Cornelius F Boerkoel
Journal:  Hum Mol Genet       Date:  2012-02-28       Impact factor: 6.150

Review 4.  Factors influencing disease phenotype and penetrance in HFE haemochromatosis.

Authors:  J Rochette; G Le Gac; K Lassoued; C Férec; K J H Robson
Journal:  Hum Genet       Date:  2010-07-06       Impact factor: 4.132

5.  Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload.

Authors:  Monique G Zaahl; Alison T Merryweather-Clarke; Maritha J Kotze; Schalk van der Merwe; Louise Warnich; Kathryn J H Robson
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

6.  Total blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes.

Authors:  James C Barton; Ronald T Acton; Howard W Wiener; Rodney Cp Go
Journal:  BMC Blood Disord       Date:  2005-07-25

7.  Effects of highly conserved major histocompatibility complex (MHC) extended haplotypes on iron and low CD8+ T lymphocyte phenotypes in HFE C282Y homozygous hemochromatosis patients from three geographically distant areas.

Authors:  Mónica Costa; Eugénia Cruz; James C Barton; Ketil Thorstensen; Sandra Morais; Berta M da Silva; Jorge P Pinto; Cristina P Vieira; Jorge Vieira; Ronald T Acton; Graça Porto
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.